

University of Dundee

**Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes**

Perry, John R. B.; Weedon, Michael N.; Langenberg, Claudia; Jackson, Anne U.; Lyssenko, Valeriya; Sparso, Thomas

*Published in:*  
Human Molecular Genetics

*DOI:*  
[10.1093/hmg/ddp522](https://doi.org/10.1093/hmg/ddp522)

*Publication date:*  
2010

*Licence:*  
CC BY-NC

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Perry, J. R. B., Weedon, M. N., Langenberg, C., Jackson, A. U., Lyssenko, V., Sparso, T., Thorleifsson, G., Grallert, H., Ferrucci, L., Maggio, M., Paolisso, G., Walker, M., Palmer, C. N. A., Payne, F., Young, E., Herder, C., Narisu, N., Morken, M. A., Bonnycastle, L. L., ... Frayling, T. M. (2010). Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. *Human Molecular Genetics*, 19(3), 535-544. <https://doi.org/10.1093/hmg/ddp522>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes

John R.B. Perry<sup>1</sup>, Michael N. Weedon<sup>1</sup>, Claudia Langenberg<sup>2</sup>, Anne U. Jackson<sup>3</sup>, Valeriya Lyssenko<sup>4</sup>, Thomas Sparsø<sup>5</sup>, Gudmar Thorleifsson<sup>6</sup>, Harald Grallert<sup>7</sup>, Luigi Ferrucci<sup>8</sup>, Marcello Maggio<sup>9</sup>, Giuseppe Paolisso<sup>10</sup>, Mark Walker<sup>11</sup>, Colin N.A. Palmer<sup>12</sup>, Felicity Payne<sup>13</sup>, Elizabeth Young<sup>2</sup>, Christian Herder<sup>14</sup>, Narisu Narisu<sup>15</sup>, Mario A. Morken<sup>15</sup>, Lori L. Bonnycastle<sup>15</sup>, Katharine R. Owen<sup>16</sup>, Beverley Shields<sup>1</sup>, Beatrice Knight<sup>1</sup>, Amanda Bennett<sup>16</sup>, Christopher J. Groves<sup>16</sup>, Aimo Ruukonen<sup>17</sup>, Marjo Riitta Jarvelin<sup>18</sup>, Ewan Pearson<sup>12</sup>, Laura Pascoe<sup>11</sup>, Ele Ferrannini<sup>19</sup>, Stefan R. Bornstein<sup>20</sup>, Heather M. Stringham<sup>3</sup>, Laura J. Scott<sup>3</sup>, Johanna Kuusisto<sup>21</sup>, Peter Nilsson<sup>4</sup>, Malin Neptin<sup>4</sup>, Anette P. Gjesing<sup>5</sup>, Charlotta Pisinger<sup>22</sup>, Torsten Lauritzen<sup>23</sup>, Anelli Sandbaek<sup>23</sup>, Mike Sampson<sup>25</sup>, MAGIC, Ele Zeggini<sup>26</sup>, Cecilia M. Lindgren<sup>16,27</sup>, Valgerdur Steinthorsdottir<sup>6</sup>, Unnur Thorsteinsdottir<sup>6</sup>, Torben Hansen<sup>5,28</sup>, Peter Schwarz<sup>20</sup>, Thomas Illig<sup>7</sup>, Markku Laakso<sup>21</sup>, Kari Stefansson<sup>6</sup>, Andrew D. Morris<sup>12</sup>, Leif Groop<sup>4</sup>, Oluf Pedersen<sup>5,24,29</sup>, Michael Boehnke<sup>3</sup>, Inês Barroso<sup>13</sup>, Nicholas J. Wareham<sup>2</sup>, Andrew T. Hattersley<sup>1</sup>, Mark I. McCarthy<sup>16,27</sup> and Timothy M. Frayling<sup>1,\*</sup>

<sup>1</sup>Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Magdalen Road, Exeter EX1 2LU, UK, <sup>2</sup>MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK, <sup>3</sup>Department of Biostatistics, Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA, <sup>4</sup>Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, University Hospital Malmö, Malmö, Sweden, <sup>5</sup>Hagedorn Research Institute, 2820 Gentofte, Denmark, <sup>6</sup>deCODE Genetics, 101 Reykjavik, Iceland, <sup>7</sup>Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany, <sup>8</sup>Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, NIH, Baltimore, MD, USA, <sup>9</sup>Department of Internal Medicine and Medical Sciences, Section of Geriatrics, University of Parma, Parma, Italy, <sup>10</sup>Department of Geriatrics and Metabolic Diseases Second, University of Naples, Naples, Italy, <sup>11</sup>Diabetes Research Group, School of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, UK, <sup>12</sup>Biomedical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK, <sup>13</sup>Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK, <sup>14</sup>Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany, <sup>15</sup>Genome Technology Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA, <sup>16</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Old Road, Headington Oxford OX3 7LJ, UK, <sup>17</sup>Institute of Diagnostics, Clinical Chemistry and <sup>18</sup>Institute of Health Sciences and Biocenter Oulu, University of Oulu, Box 5000, Fin90014, Finland, <sup>19</sup>Department of Internal Medicine, University of Pisa, School of Medicine, Pisa, Italy, <sup>20</sup>Department of Medicine III, Division Prevention and Care of Diabetes, University of Dresden, 01307 Dresden, Germany <sup>21</sup>Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio 70210, Finland, <sup>22</sup>Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark, <sup>23</sup>Faculty of Health

\*To whom correspondence should be addressed. Tel: +44 1392722935; Fax: +44 1392722926; Email: tim.frayling@pms.ac.uk

© The Author 2009. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/2.5>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sciences and <sup>24</sup>Institute of Biomedical Science, University of Copenhagen, Copenhagen, Denmark <sup>25</sup>Department of Endocrinology and Diabetes, Norfolk and Norwich University Hospital NHS Trust, Norwich NR1 7UY, UK, <sup>26</sup>Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK, <sup>27</sup>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK, <sup>28</sup>Faculty of Health Science, University of Southern Denmark, Odense, Denmark and <sup>29</sup>Faculty of Health, University of Aarhus, Aarhus, Denmark

Received September 10, 2009; Revised and Accepted November 16, 2009

**Epidemiological studies consistently show that circulating sex hormone binding globulin (SHBG) levels are lower in type 2 diabetes patients than non-diabetic individuals, but the causal nature of this association is controversial. Genetic studies can help dissect causal directions of epidemiological associations because genotypes are much less likely to be confounded, biased or influenced by disease processes. Using this Mendelian randomization principle, we selected a common single nucleotide polymorphism (SNP) near the *SHBG* gene, rs1799941, that is strongly associated with SHBG levels. We used data from this SNP, or closely correlated SNPs, in 27 657 type 2 diabetes patients and 58 481 controls from 15 studies. We then used data from additional studies to estimate the difference in SHBG levels between type 2 diabetes patients and controls. The *SHBG* SNP rs1799941 was associated with type 2 diabetes [odds ratio (OR) 0.94, 95% CI: 0.91, 0.97;  $P = 2 \times 10^{-5}$ ], with the SHBG raising allele associated with reduced risk of type 2 diabetes. This effect was very similar to that expected (OR 0.92, 95% CI: 0.88, 0.96), given the *SHBG*-SNP versus SHBG levels association (SHBG levels are 0.2 standard deviations higher per copy of the A allele) and the SHBG levels versus type 2 diabetes association (SHBG levels are 0.23 standard deviations lower in type 2 diabetic patients compared to controls). Results were very similar in men and women. There was no evidence that this variant is associated with diabetes-related intermediate traits, including several measures of insulin secretion and resistance. Our results, together with those from another recent genetic study, strengthen evidence that SHBG and sex hormones are involved in the aetiology of type 2 diabetes.**

## INTRODUCTION

Circulating sex hormone levels are associated with type 2 diabetes, but the causal nature of these associations is controversial. Many observational epidemiological studies have described associations between type 2 diabetes and androgens (primarily testosterone), estrogens (estradiol) and their circulating binding protein, sex hormone binding protein (SHBG) (1). Meta-analyses of these studies show consistent sex-specific associations. In men, lower testosterone, higher estradiol and lower SHBG levels are associated with type 2 diabetes. In women, higher testosterone, higher estradiol and lower SHBG are associated with type 2 diabetes (1).

The differences in sex hormone levels between type 2 diabetes patients and controls are complicated by increased adiposity, which is also associated with reduced SHBG. However, differences in adiposity cannot fully explain the associations between sex hormones and type 2 diabetes. In both men and women, the differences in testosterone, estradiol and SHBG levels between type 2 diabetes patients and non-diabetic individuals remain very similar before and after controlling for BMI, age, ethnic background and, in females, menopausal status (1).

There is evidence that the associations between sex hormones and type 2 diabetes may be causal. First, a recent study described an association between two SNPs in the *SHBG* gene and type 2 diabetes (2). Second, prospective studies show that the levels of sex hormones are altered in individuals

diagnosed many years later (1). Third, hyper-androgenic disorders such as polycystic ovarian syndrome (PCOS) in women result in an increased risk of type 2 diabetes and are very strongly associated with insulin resistance (3). In men, androgen supplementation in the presence of central obesity and low testosterone levels increases insulin sensitivity (4–6). Fourth, male rats lacking the androgen receptor are insulin resistant (7) and female rats treated with testosterone after oophorectomy become insulin resistant (8), findings that are consistent with the sex-specific associations seen in humans.

Despite some evidence pointing towards a causal role of sex hormones in type 2 diabetes, further evidence is required. The recent genetic study involved a relatively small number of patients (359 women and 170 men), the effect sizes, with odds ratios (ORs) of 1.52 and 1.39, are similar to those for SNPs in the *TCF7L2* gene (9), which raises doubt as to why these associations were not found by genome-wide association approaches, and the evidence of association between *SHBG* SNPs and type 2 diabetes was not strong ( $P = 0.02$  for each SNP under the best model) (2). It is well known that even well-conducted, well-controlled epidemiological associations can often be confounded by imperfect measurement of known, or unknown, related factors. Prospective studies establish whether or not a risk factor is present prior to disease diagnosis, but do not necessarily solve the concerns about epidemiological studies. Disease processes can start many years before disease diagnosis, which means that altered hormone levels observed prospectively could be a

consequence rather than cause of early disease processes. The causal direction of the associations between hyper-androgenism and insulin resistance in PCOS is not known. Studies in animals may not be relevant to humans and human trials of androgen therapy have focused on people with extreme levels of obesity or circulating hormones and conflicting results have been reported (10,11). Finally, insulin lowering interventions in non-diabetic men and women (without PCOS) lead to increased SHBG levels, suggesting that insulin can causally influence sex hormone dynamics (12,13).

Genetic studies can be a valuable additional tool which help to dissect causal directions of epidemiological associations (14). In most situations, alleles at genetic variants are randomly distributed between individuals who differ by conventional confounding factors. This 'Mendelian randomization' principle has been used recently in the context of metabolic traits to provide evidence that lifelong exposure to slightly raised C-reactive protein (CRP) (15), Interleukin-18 (IL18) (16), regulated on activation, normal T-cell expressed and secreted protein (RANTES) (17) or beta-carotene (18) levels are unlikely to alter the risk of type 2 diabetes, whereas some evidence for an aetiological association has been suggested for macrophage migration inhibitory factor (MIF) (19). Other examples of this approach provide mechanistic insight to disease. For example the association between variation in the *FTO* gene, that is associated with adiposity, and some cancers, provides some evidence that adiposity has an aetiological role in cancer (20).

In this study, we used the principle of Mendelian Randomization to provide evidence for or against an aetiological role of raised SHBG levels and reduced risk of type 2 diabetes. Our results indicate that higher SHBG levels may reduce the risk of type 2 diabetes.

## RESULTS

### Observed association between *SHBG* SNP and type 2 diabetes risk

We observed evidence of association between the *SHBG* SNP rs1799941 and type 2 diabetes (OR 0.94, 95% CI: 0.91, 0.97;  $P = 2 \times 10^{-5}$ ), with the SHBG raising allele associated with reduced risk of type 2 diabetes (Figs 1 and 2). This result included correction for age, sex and BMI across 14 of the 15 studies (one study is uncorrected), but the result was similar when correcting for age and sex only (OR 0.94, 95% CI: 0.91, 0.97;  $P = 2 \times 10^{-5}$ ). The result was also similar in men (OR 0.95, 95% CI: 0.91, 0.99;  $P = 0.009$ ); and women (OR 0.93, 95% CI: 0.89, 0.98;  $P = 0.003$ ). There was no evidence of heterogeneity in any analysis, either between or within sexes or with and without correction for BMI (all heterogeneity  $P > 0.15$ , maximum I<sup>2</sup>—a measure of the variation in effect size attributable to heterogeneity—29%). There was a trend towards an increased effect in carriers of two copies of the SHBG raising allele, compared with carriers of two copies of the SHBG lowering allele (OR 0.91, 95% CI: 0.85, 0.97;  $P = 0.006$ ) (uncorrected). The SHBG lowering (G) allele at rs1799941 ranged in allele frequency from 0.72 to 0.75 in individual study controls and from 0.73 to 0.77 in individual study type 2 diabetes patients.

### Observed differences in SHBG levels between type 2 diabetes patients and controls

Details of the differences in SHBG levels between type 2 diabetes patients and controls are given in Table 2 and in Figures 1 and 3. SHBG levels were 0.233 (95% CI: -0.35, -0.115) standard deviations lower in type 2 diabetes patients compared with controls, when controlling for BMI. This estimate differed little between men (OR -0.218, 95% CI: -0.360, -0.076) and women (OR -0.264, 95% CI: -0.475, -0.054).

### Approximate expected association between *SHBG* SNP and type 2 diabetes risk


We next tested whether or not the observed association between the *SHBG* SNP and type 2 diabetes was consistent with that expected if SHBG levels alter the risk of type 2 diabetes. We used the estimates of the effect of rs1799941 on circulating SHBG levels and the difference in SHBG levels between type 2 diabetes patients and controls to calculate an approximate expected effect of rs1799941 with type 2 diabetes (Fig. 1). The expected associations were: for men and women combined (OR 0.92, 95% CI: 0.88, 0.96); for men (OR 0.92, 95% CI: 0.88, 0.97); and for women (OR 0.91, 95% CI: 0.84, 0.98). These estimates were similar to those observed.

### Associations between *SHBG* SNPs and type 2 diabetes related intermediate traits


We did not detect any association between the *SHBG* SNP rs1799941 (or its close proxy rs12150660) and any measures of intermediate type 2 diabetes related traits in population-based studies. These included fasting insulin ( $P = 0.11$ ,  $N = 37\,864$ ), the HOMAIR measure of insulin resistance ( $P = 0.24$ ,  $N = 36\,601$ ), fasting glucose ( $P = 0.52$ ,  $N = 45\,691$ ), the HOMAB measure of beta-cell function ( $P = 0.04$ ,  $N = 36,135$ ) [all rs12150660], insulin secretion as assessed by oral glucose tolerance test-based measures of glucose, insulin and C-peptide at 30 and 120 min (all  $P > 0.14$ ,  $N = 5771$ ) or insulin resistance as measured by hyperinsulinaemic-euglycaemic clamps ( $P = 0.94$ ,  $N = 1229$ ) [all rs1799941].

## DISCUSSION

Our study provides evidence that raised circulating SHBG levels reduce the risk of type 2 diabetes. Our results, together with those from the recent study by Ding *et al.* (2), provide insight into the role of sex hormones in the aetiology of type 2 diabetes. It has been known for some time that circulating SHBG levels are lower in people with type 2 diabetes compared with non-diabetic individuals, both in cross-sectional comparisons and prospectively. Despite this association, there has been considerable doubt as to the causal relevance of sex hormones in type 2 diabetes. The two genetic studies therefore add considerably to the argument that sex hormones are involved in the aetiology of the disease. This may have important implications for the treatment of diabetes or hypo- and hyper-androgenism in the two sexes.




**Figure 1.** Triangulation approach to assess how the observed association of the *SHBG* SNP rs1799941 with type 2 diabetes compares with that expected given the association between rs1799941 and circulating SHBG levels and the difference in SHBG levels between type 2 diabetes patients and controls.



**Figure 2.** Meta-analysis of rs1799941 in type 2 diabetes case-control studies correcting for or matching for BMI, age and sex. OR, odds ratio.

There are several strengths to our study. First, genotypes are randomly distributed in ethnically homogenous populations, meaning our results are very unlikely to be confounded or biased or secondary to diabetes disease processes. Second,

the statistical confidence of the association between the *SHBG* variant and type 2 diabetes is very strong—of approximately 1 million independent common variants in European genomes, we would only expect 20 to reach this level of



**Figure 3.** Details of the correlations between SHBG levels and type 2 diabetes from seven cross-sectional studies of European individuals correcting or matching for BMI or waist circumference.

statistical confidence by chance. Our results are consistent across 15 studies comprising 27 657 type 2 diabetic patients and 58 481 controls, with all but two studies showing an OR in the expected direction. Third, the ORs we observe between the *SHBG* rs1799941 SNP and type 2 diabetes are consistent with those expected from a triangulation approach. Fourth, the use of a SNP at the *SHBG* gene locus strongly associated with circulating SHBG levels means the association is very unlikely to be due to a pleiotropic effect of the variant on another pathway.

There are a few limitations to our study. Most notably we have not found any evidence for the mechanism behind the association between SHBG levels and type 2 diabetes. Despite the large numbers available, we did not observe any associations with various measures of insulin resistance or insulin secretion. This lack of association with intermediate type 2 diabetes traits is not inconsistent with the association with type 2 diabetes. The OR of 0.94 (equivalent to 1.06 for the SHBG lowering allele) is small and previous studies of variants of this magnitude have often not identified any associations with measures of insulin resistance or insulin secretion (21). This may in part be due to the reproducibility of measures based on insulin, which has a very short half life and fluctuates appreciably within individuals. We note, however, that the small effect size does not mean the finding has any less relevance to the question of aetiology, which relies only on the statistical confidence of the findings.

A further caveat to our study is that we used a different and much smaller set of patients and controls to estimate the magnitude of the association between circulating SHBG levels and type 2 diabetes compared with the association between the *SHBG* SNP and type 2 diabetes. This difference meant that the estimated effect is very approximate and may be biased by the availability of data from previous publications. The confidence intervals of our estimated effect do not take into account the error in the estimate of the SNP-SHBG levels and so this adds further to the uncertainty of this calculation. Despite these concerns, the estimated and observed ORs for the *SHBG* SNP effect on type 2 diabetes were very similar.

There are some notable differences between our study and that of Ding *et al.* (2). While both studies support an association between *SHBG* SNPs and type 2 diabetes, the effect sizes are very different. Ding *et al.* report ORs of 1.52 (0.66 inverted) and 1.39 for rs6259 and rs6257, respectively. These ORs are similar to those for SNPs in the *TCF7L2* gene, which represent the most strongly associated SNPs in genome wide association studies of type 2 diabetes. There is no evidence of association between rs6259 (a non-synonymous SNP, D356N) and type 2 diabetes in data from 4549 cases and 5579 controls [ $P=0.72$ , OR 1.02 [0.92–1.12], all of European ancestry] (22), and this SNP appears to be less strongly associated with SHBG levels than rs1799941, based on data from previous studies (23,24). The other SNP reported by Ding *et al.*, rs6257, is not in HapMap

but previously published data (25) indicates that rs1799941 and rs6257 are partially correlated and that rs1799941 drives the association with SHBG levels. These observations, together with our much larger sample size, suggest that the small OR of 0.94 is a closer reflection of the true effect size than that reported by Ding *et al.*

How might genetically lowered SHBG levels increase the risk of type 2 diabetes? Previous studies suggest that rs1799941 has different effects on total testosterone levels in men and women. Dunning *et al.* showed that the SHBG lowering allele at rs1799941 is not associated with total testosterone levels in postmenopausal women ( $N = 1975$ ) (23). This means that women with genetically lower SHBG levels are exposed to proportionally more of the adverse effects of the biologically active unbound testosterone. In contrast, higher testosterone levels are thought to protect against adverse metabolic effects in men and Ahn *et al.* (25) showed that the SHBG raising allele at rs1799941 is strongly associated with higher total testosterone levels in men ( $N = 4678$ ). This explanation is complicated by the fact that free testosterone levels are maintained in men by a strong feedback loop whereby luteinizing hormone (LH) production from the pituitary gland in the presence of low androgen levels stimulates testosterone production in the testes. This should mean that genetically lower SHBG levels will not greatly affect free testosterone levels in men. However, there is recent evidence that bound testosterone may be biologically active (26). If this is the case, then men with lower total testosterone due to lower SHBG will be exposed to less of the protective metabolic effects of androgens, despite similar levels of unbound testosterone.

There are additional implications of our results that require further study. First, our results and those of Ding *et al.* are not altered by adjustment or matching for BMI despite the fact that increased BMI and adiposity are correlated with reduced SHBG levels. This could mean that altered SHBG levels are part of the reason why increased BMI causally increases the risk of type 2 diabetes. Second, a SNP (rs6259) in the *SHBG* gene has been associated with prostate cancer and there is increasing evidence that there may be a causal link to the inverse association between prostate cancer and type 2 diabetes (27), although our results suggest that this requires additional studies of rs1799941 in prostate cancer (28).

In conclusion, a large type 2 diabetes case–control study provides strong statistical support for a role of SHBG and sex hormones in the aetiology of type 2 diabetes.

## MATERIALS AND METHODS

Our methods were based on the triangulation approach outlined in Figure 1. In summary we used (i) a common single nucleotide polymorphism (SNP) near the *SHBG* gene, rs1799941, previously shown to be very strongly associated with SHBG levels; (ii) 27 657 type 2 diabetes patients and 58 481 controls from 15 studies to test the association between this SNP and type 2 diabetes risk; (iii) data from six studies to estimate the magnitude of the association between SHBG levels and type 2 diabetes and (iv) existing

data to calculate an approximate expected effect of the *SHBG* SNP on type 2 diabetes given the magnitude of the SNP versus SHBG levels association and the magnitude of the SHBG levels versus type 2 diabetes association.

### Selection of a SNP strongly associated with SHBG levels

Several genetic studies have established unequivocal evidence that common variation close to the *SHBG* gene influences circulating SHBG levels. We used previously published information to quantify the association between a SNP, rs1799941, 67 base pairs upstream of the *SHBG* gene and circulating SHBG levels. Several studies have shown consistent associations between rs1799941 and SHBG levels ( $P < 1 \times 10^{-16}$ ) (23–25). Each copy of the A allele is associated with a 0.20 SDs increase in SHBG levels, based on Finnish (NFBC66) and Italian (InCHIANTI) population-based studies, with similar effect sizes in men and women (24).

### Observed association between *SHBG* SNP and type 2 diabetes risk

Through collaboration between 15 studies, we assembled a set of 27 657 cases and 58 481 controls. These studies varied in characteristics and ascertainment criteria and details are given in Table 1. All patients and controls were of European ancestry. The *SHBG* SNP rs1799941 was directly genotyped in all but three studies, two of which used a strongly correlated SNP (rs12150660  $r^2 = 0.9$  with rs1799941), available as part of genome wide association data (FUSION1 and DGI), and a third used a mixture of directly genotyped and imputed data (Decode). Genotyping methods and quality control steps are given in Supplementary Material, Table S1. Individual studies calculated a per allele OR for the A allele at rs1799941, correcting for age, sex and BMI (except publicly available DGI data where cases and controls were matched for gender and BMI, and WTCCC samples, where data for BMI in controls was not available). The FUSION2 study additionally corrected for birth province and used 5 year age category instead of age. We next used the ‘metan’ command in STATAv10 to meta-analyse these results across all 15 studies. This function weighs all studies by the inverse of their variance (a function of SNP frequency and study size) to obtain a per allele estimate of the type 2 diabetes OR for all studies. We quote the OR effect of the SHBG raising allele, which, because raised SHBG levels are correlated with reduced risk of type 2 diabetes, we expected to be  $< 1.0$ , if SHBG levels are involved in the aetiology of type 2 diabetes. Given the different levels of SHBG in men and women we repeated analyses stratified by sex.

### Observed differences in SHBG levels between type 2 diabetes patients and controls

SHBG levels are not routinely measured in type 2 diabetes patients and controls. Instead, we used data from type 2 diabetes studies (four of men only and three of women only) that had measured SHBG levels. These studies were men and women from the InCHIANTI study (24) and the cross-sectional studies published in the meta-analysis conducted

**Table 1.** Characteristics of type 2 diabetes patients and controls from 15 studies

Study	Type 2 diabetes					Control				
	N	Age Mean	SD	BMI Mean	SD	N	Age Mean	SD	BMI Mean	SD
<b>Men</b>										
WTCCC	1334	50.15	9.08	30.43	5.32	1042	N/A	N/A	N/A	N/A
Dundee	2205	55.38	8.81	30.78	5.36	2283	59.98	11.41	27.16	3.95
EFS-Y2D	102	40	5.45	30.63	4.9	861	32.7	5.97	26.59	3.87
Danish	2049	56.55	8.87	30.24	4.88	2252	47.06	9.16	26.11	3.52
DGI <sup>a</sup>	742	N/A	N/A	N/A	N/A	707	N/A	N/A	N/A	N/A
Malmö CC	1641	56.76	11	29.09	4.9	1287	57.7	6.08	25.52	3.08
FUSION1 <sup>a,b</sup>	623	53.59	9.09	29.44	4.02	573	63.42	7.62	27.02	3.52
KORA <sup>b</sup>	669	60.4	9.1	29.7	4.7	840	60.5	9	28	3.9
Cambridgeshire CC <sup>b</sup>	346	63.4	7.9	28.7	3.8	343	63.7	7.9	27.1	3.5
ADDITION/ELY <sup>b</sup>	553	60.2	7.5	32.3	5.4	725	61.2	9.2	27.1	3.9
NDCCS <sup>b</sup>	3,575	66.4	10.6	29.3	4.8	3,038	58.9	9.1	26.3	3.1
DeCODE	832	55	12.1	29.7	4.9	7603	64.3	16.4	27.4	4.5
FUSION2	646	58.3	8.82	30.23	4.96	724	57.45	7.58	26.74	3.41
METSIM <sup>c</sup>	818	60.84	5.99	30.07	5.2	3372	57.98	6.4	26.25	3.46
DIAGEN	255	62.55	11.06	29.25	4.46	267	55.87	14.38	26.52	3.48
Total	16 390					25 917				
<b>Women</b>										
WTCCC	951	49.82	9.56	32.86	7.08	1039	N/A	N/A	N/A	N/A
Dundee	1666	56.36	8.98	32.82	6.83	2414	56.97	12.04	26.89	5.17
EFS-YT2D	89	37.88	7.18	34.14	7.78	901	30.44	5.25	23.97	4.39
Danish	1398	57.35	9.89	31.28	6.28	2607	46.81	8.97	25.08	4.39
DGI <sup>a</sup>	722	N/A	N/A	N/A	N/A	760	N/A	N/A	N/A	N/A
Malmö CC	1150	59.46	11.89	30.46	6.13	2210	57.34	5.96	24.79	3.83
FUSION1 <sup>a,b</sup>	470	54.03	8.98	31.2	5.25	599	63.71	7.27	27.24	4.14
KORA <sup>b</sup>	538	61.6	9.4	31.8	5.8	678	61.4	9.2	27.9	4.7
Cambridgeshire CC <sup>b</sup>	202	63.3	7.9	31.6	6.8	191	63.5	7.7	27.8	5.1
ADDITION/ELY <sup>b</sup>	339	62.9	6.4	34.2	6	885	60.5	9.1	27.1	5.4
NDCCS <sup>b</sup>	2,481	67.1	11.4	30.8	6.5	3,390	57.8	9.3	25.9	4
DeCODE	582	55.2	12.7	30.6	6	16007	57.2	18.2	26.5	5.2
FUSION2	437	61.09	7.45	31.75	5.76	463	60.92	7.34	27.14	4.6
DIAGEN	242	67.49	12.3	31.09	7	420	55.93	14.09	26.62	4.78
Total	11 267					32 564				

N/A, clinical characteristics not available separated by sex. Age is the age at diagnosis for diabetic patients unless otherwise stated.

<sup>a</sup>DGI and FUSION1 studies used proxy SNP ( $r^2 = 0.9$ ) from GWAS data rs12150660.

<sup>b</sup>Age at recruitment given for these studies.

<sup>c</sup>METSIM is a study of men only.

by Ding *et al.* (1), for which we were able to retrieve mean and standard deviation measures of SHBG in cases and controls, were restricted to individuals of European ancestry, and had matched or corrected SHBG levels for body mass index or waist circumference. Details of these studies are given in Table 2. For each study, we tabulated six variables: number of cases, mean case SHBG levels, standard deviation of case SHBG levels, number of controls, mean control SHBG levels and standard deviation of control SHBG levels, using  $\text{ngml}^{-1}$  as the units of SHBG. We performed an inverse variance weighted meta-analysis of these studies, both overall and within sexes, using the 'metan' command in STATAv10, to derive a standardized mean difference (SMD) of SHBG levels between type 2 diabetes cases and controls.

#### Approximation of the expected association between SHBG SNP and type 2 diabetes risk

We used the estimates of the effect of rs1799941 on SHBG levels in (i) and the correlation between SHBG levels and type 2 diabetes estimated in (iii) to calculate an approximate

expected effect of rs1799941 on type 2 diabetes, assuming that there is an aetiological association between SHBG levels and type 2 diabetes risk. We used the formula:

$$\text{OR}_{\text{expected}} = \exp(1.81 \times (\text{SD}_A \times \text{SMD}_B))$$

where  $\text{SD}_A$  is the per allele effect of rs1799941 on circulating SHBG levels expressed as a standard deviation and  $\text{SMD}_B$  is the standardized mean difference (SMD) of SHBG levels between type 2 diabetes cases and controls. This approach has previously been described in the context of diabetes-related traits (29) and the rationale for the formula for approximating SMDs to ORs is described in more detail in Chinn *et al.* (30). The figure 1.81 is the scaling factor used to approximate  $\ln(\text{ORs})$  to and from standardized mean differences (30).

#### Associations between SHBG SNP and type 2 diabetes related traits

To test for associations between the SHBG SNP rs1799941 (or its close proxy rs12150660) and type 2 diabetes related traits,



**Table 2.** Details of SHBG levels in type 2 diabetes patients and normal glycaemic individuals in seven cross-sectional studies

	Type 2 diabetic patients					Controls				
	N	Age (SD)	BMI (SD)	SHBG Mean	SD	N	Age (SD)	BMI (SD)	SHBG Mean	SD
<b>Men</b>										
Abate <i>et al.</i> (34) <sup>a</sup>	33	55 (9)	27.6 (5.0)	19.10	13.00	24	45 (9)	28.2 (7.6)	19.10	13.00
Svartberg <i>et al.</i> (35) <sup>b</sup>	55	N/A	N/A	43.70	21.40	1364	N/A	N/A	51.80	22.00
Kalme <i>et al.</i> (36) <sup>c</sup>	109	N/A	N/A	63.20	29.23	152	N/A	N/A	71.60	25.20
InCHIANTI <sup>d</sup>	71	72.0 (9.4)	27.80 (3.45)	85.12	46.83	476	66.6 (16.2)	26.91 (3.36)	87.22	47.56
TOTAL	268					2016				
SMD (95%CI)										-0.218 (-0.360, -0.076)
<b>Women</b>										
Jayagopal <i>et al.</i> (37) <sup>e</sup>	12	62 (50–73)	31.6 (25.1–35.7)	38.80	18.20	11	56 (48–70)	32.0 (26.6–44.4)	42.20	17.10
Stoney <i>et al.</i> (38) <sup>f</sup>	42	64 (6.5)	28.8 (5.2)	27.80	20.50	42	63 (6.5)	28.9 (4.5)	40.30	26.12
InCHIANTI (4)	67	75.7 (9.8)	29.34 (5.05)	102.92	75.47	650	68.4 (15.8)	27.04 (4.58)	118.22	85.17
TOTAL	121					703				
SMD (95% CI)										-0.264 (-0.475, -0.054)

Data are from individuals of European ancestry matched or corrected for BMI or waist circumference. Women are postmenopausal.

SMD, standardized mean difference; N/A, not available from original publications.

<sup>a</sup>Controls selected to have the same range of BMI as cases. Controls include two individuals and cases include eight individuals of Hispanic ancestry.

<sup>b</sup>Svartberg *et al.*, SHBG means and SDs are corrected for age and waist circumference.

<sup>c</sup>Kalme *et al.*, SHBG means and SDs are corrected for BMI.

<sup>d</sup>InCHIANTI SHBG values are geometric values derived from lnSHBG levels corrected for age and BMI.

<sup>e</sup>Controls weight matched to cases. For BMI and age, median and range given.

<sup>f</sup>Stoney *et al.* controls selected to match cases for BMI and age.

we used data from a variety of sources. For measures of fasting glucose and homeostatic model assessment (HOMA) based measures of insulin resistance, we used data from MAGIC of between 36 135 and 45 691 individuals, details of which are described in detail elsewhere (31). For measures of insulin secretion, we used 5771 individuals from the Danish study, details of which are described in detail elsewhere (32). For measures of whole body/peripheral insulin resistance, we used 1229 individuals from the RISC study (33). All statistical tests were performed using appropriate transformations (described in the relevant publications) and a per allele 1.d.f. test (in keeping with the additive effect of rs1799941 on SHBG levels).

## SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

## ACKNOWLEDGEMENTS

We thank all study participants. E.Z. is a Wellcome Trust Research Career Development Fellow. We acknowledge the contribution of our team of research nurses. We acknowledge the efforts of Jane Collier, Phil Robinson, Steven Asquith and others at Kbiosciences (<http://www.kbioscience.co.uk/>) for their rapid and accurate large-scale genotyping. We are grateful to the study teams and participants. We thank the technical teams at the Wellcome Trust Sanger Institute and the MRC Epidemiology laboratory for genotyping and informatics support. The Danish Inter99 sub-study was initiated by Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee comprises the former two and Charlotta Pisinger. We thank all members of field staffs who were involved in the planning

and conduct of the MONICA/KORA Augsburg studies. FUSION: We would like to thank the many Finnish volunteers who generously participated in the FUSION, D2D, Health 2000, Finrisk 1987, Finrisk 2002 and Savitaipale studies from which we chose our FUSION GWA and replication. DIAGEN: We are grateful to all of the patients who cooperated in this study and to their referring physicians and diabetologists in Saxony. Mike Weedon is Vandervell Foundation Research Fellow. We gratefully acknowledge Prof Steve Franks for useful discussion.

*Conflict of Interest statement.* None declared.

## FUNDING

Collection of the UK type 2 diabetes cases was supported by Diabetes UK, BDA Research and the UK Medical Research Council (Biomedical Collections Strategic Grant G0000649). The UK Type 2 Diabetes Genetics Consortium collection was supported by the Wellcome Trust (Biomedical Collections Grant GR072960). The GWA genotyping was supported by the Wellcome Trust (076113) and replication genotyping by the European Commission (EURODIA LSHG-CT-2004-518153), MRC (Project Grant G016121), Wellcome Trust (Project Grant 083270/Z/07/Z), Peninsula Medical School and Diabetes UK. The work on the Cambridgeshire case-control, Ely and EPIC-Norfolk studies was funded by support from the Wellcome Trust and Medical Research Council (MRC). ADDITION-Cambridge was supported by the Wellcome Trust, MRC, National Health Service R&D support funding and the National Institute for Health Research. The Norfolk Diabetes study is funded by the MRC with support from NHS Research & Development and the Wellcome Trust. The Danish case-control study was

supported by the Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LUCAMP) and the Danish Diabetes Association. Inter99 is supported by grants from the Danish Research Council, The Danish Centre for Health Technology Assessment, Novo Nordisk Inc., Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, The Danish Heart Foundation, The Danish Pharmaceutical Association, The Augustinus Foundation and The Ib Henriksen Foundation, the Becket Foundation. The ADDITION sub-study Denmark was initiated by: Knut Borch-Johnsen (PI), Torsten Lauritzen (PI) and Anneli Sandbaek. The study was supported by the National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe and South Jutland, together with the Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, the diabetes fund of the National Board of Health, the Danish Medical Research Council, the Aarhus University Research Foundation and the Novo Nordisk Foundation. The study received unrestricted grants from Novo Nordisk, Novo Nordisk Scandinavia, Astra Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, Servier Denmark and HemoCue Denmark. The KORA studies were financed by the Helmholtz Zentrum München, Research Center for Environment and Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF), the German National Genome Research Network (NGFN) and the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. Additional funds were provided by the German Diabetes Center (Düsseldorf, Germany), the Federal Ministry of Health (Berlin, Germany) and the Ministry of Innovation, Science, Research and Technology of the state North Rhine-Westphalia (Düsseldorf, Germany). The RISC Study is supported by European Union grant QLGI-CT-2001-01252 and AstraZeneca. Support for FUSION study was provided by the following: American Diabetes Association grant 1-05-RA-140 (R.M.W.) and NIH grants DK069922 (R.M.W.), U54 DA021519 (R.M.W.), DK062370 (M.B.) and DK072193 (K.L.M.). Additional support comes from the National Human Genome Research Institute intramural project number 1 Z01 HG000024 (F.S.C.). DIAGEN study was supported by the Dresden University of Technology funding grant, Med Drive. METSIM: support was provided by grant 124243 from the Academy of Finland. The InCHIANTI study is supported in part by the Intramural Research Program of the NIH, National Institute on Aging and in part by NIH/NIA grant R01 AG24233-01. I.B. is supported by the Wellcome Trust (077016/Z/05/Z). Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.

## REFERENCES

- Ding, E.L., Song, Y., Malik, V.S. and Liu, S. (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*, **295**, 1288–1299.
- Ding, E.L., Song, Y., Manson, J.E., Hunter, D.J., Lee, C.C., Rifai, N., Buring, J.E., Gaziano, J.M. and Liu, S. (2009) Sex hormone-binding globulin and risk of type 2 diabetes in women and men. *N. Engl. J. Med.*, **361**, 1152–1163.
- Dunaif, A. (1995) Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. *Am. J. Med.*, **98**, 33S–39S.
- Marin, P., Holmang, S., Jonsson, L., Sjostrom, L., Kvist, H., Holm, G., Lindstedt, G. and Bjorntorp, P. (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. *Int. J. Obes. Relat. Metab. Disord.*, **16**, 991–997.
- Simon, D., Charles, M.A., Lahlou, N., Nahoul, K., Oppert, J.M., Gouault-Heilmann, M., Lemort, N., Thibault, N., Joubert, E., Balkau, B. *et al.* (2001) Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. *Diabetes Care*, **24**, 2149–2151.
- Boyanov, M.A., Boneva, Z. and Christov, V.G. (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. *Aging Male*, **6**, 1–7.
- Lin, H.Y., Xu, Q., Yeh, S., Wang, R.S., Sparks, J.D. and Chang, C. (2005) Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. *Diabetes*, **54**, 1717–1725.
- Rincon, J., Holmang, A., Wahlstrom, E.O., Lonnroth, P., Bjorntorp, P., Zierath, J.R. and Wallberg-Henriksson, H. (1996) Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. *Diabetes*, **45**, 615–621.
- Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadóttir, A. *et al.* (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat. Genet.*, **38**, 320–323.
- Liu, P.Y., Wishart, S.M., Celermajor, D.S., Jimenez, M., Pierro, I.D., Conway, A.J. and Handelsman, D.J. (2003) Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. *Eur. J. Endocrinol. Eur. Federation Endocr. Soc.*, **148**, 55–66.
- Corrales, J.J., Burgo, R.M., Garca-Berrola, B., Almeida, M., Alberca, I., Gonzalez-Buitrago, J.M., Orfao, A. and Miralles, J.M. (2004) Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. *Metabolism*, **53**, 666–672.
- Pasquali, R., Casimirri, F., De Iasio, R., Mesini, P., Boschi, S., Chierici, R., Flaminia, R., Biscotti, M. and Vicennati, V. (1995) Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. *J. Clin. Endocrinol. Metabol.*, **80**, 654–658.
- Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G.E., Filicori, M. and Morselli-Labate, A.M. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. *J. Clin. Endocrinol. Metabol.*, **85**, 2767–2774.
- Davey Smith, G. and Ebrahim, S. (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*, **32**, 1–22.
- Brunner, E.J., Kivimaki, M., Witte, D.R., Lawlor, D.A., Davey Smith, G., Cooper, J.A., Miller, M., Lowe, G.D., Rumley, A., Casas, J.P. *et al.* (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. *PLoS Med.*, **5**, e155.
- Rafiq, S., Melzer, D., Weedon, M.N., Lango, H., Saxena, R., Scott, L.J., Palmer, C.N., Morris, A.D., McCarthy, M.I., Ferrucci, L. *et al.* (2008) Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. *Diabetologia*, **51**, 2205–2213.
- Herder, C., Illig, T., Baumert, J., Muller, M., Klopp, N., Khuseynova, N., Meisinger, C., Poschen, U., Martin, S., Koenig, W. *et al.* (2008) RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. *Eur. J. Endocrinol. Eur. Federation Endocr. Soc.*, **158**, R1–R5.
- Perry, J.R., Ferrucci, L., Bandinelli, S., Guralnik, J., Semba, R.D., Rice, N., Melzer, D., Saxena, R., Scott, L.J., McCarthy, M.I. *et al.* (2009) Circulating beta-carotene levels and type 2 diabetes—cause or effect? *Diabetologia*, **52**, 2117–2121.
- Herder, C., Klopp, N., Baumert, J., Muller, M., Khuseynova, N., Meisinger, C., Martin, S., Illig, T., Koenig, W. and Thorand, B. (2008)

- Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002. *Diabetologia*, **51**, 276–284.
20. Brennan, P., McKay, J., Moore, L., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D. *et al.* (2009) Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. *Int. J. Epidemiol.*, **38**, 971–975.
  21. Grarup, N., Andersen, G., Krarup, N.T., Albrechtsen, A., Schmitz, O., Jorgensen, T., Borch-Johnsen, K., Hansen, T. and Pedersen, O. (2008) Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9 and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. *Diabetes*, **57**, 2534–2540.
  22. Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F., Marchini, J.L., Hu, T., de Bakker, P.I., Abecasis, G.R., Almgren, P., Andersen, G. *et al.* (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat. Genet.*, **40**, 638–645.
  23. Dunning, A.M., Dowsett, M., Healey, C.S., Tee, L., Luben, R.N., Folkard, E., Novik, K.L., Kelemen, L., Ogata, S., Pharoah, P.D. *et al.* (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. *J. Natl Cancer Inst.*, **96**, 936–945.
  24. Melzer, D., Perry, J.R., Hernandez, D., Corsi, A.M., Stevens, K., Rafferty, I., Lauretani, F., Murray, A., Gibbs, J.R., Paolisso, G. *et al.* (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS Genet.*, **4**, e1000072.
  25. Ahn, J., Schumacher, F.R., Berndt, S.I., Pfeiffer, R., Albanes, D., Andriole, G.L., Ardanaz, E., Boeing, H., Bueno-de-Mesquita, B., Chanock, S.J. *et al.* (2009) Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). *Hum. Mol. Genet.*, **18**, 3749–3757.
  26. Hammes, A., Andreassen, T.K., Spoelgen, R., Raila, J., Hubner, N., Schulz, H., Metzger, J., Schweigert, F.J., Luppa, P.B., Nykjaer, A. *et al.* (2005) Role of endocytosis in cellular uptake of sex steroids. *Cell*, **122**, 751–762.
  27. Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J.T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudbjartsson, D., Agnarsson, B.A., Baker, A. *et al.* (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. *Nat. Genet.*, **39**, 977–983.
  28. Berndt, S.I., Chatterjee, N., Huang, W.Y., Chanock, S.J., Welch, R., Crawford, E.D. and Hayes, R.B. (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. *Cancer Epidemiol. Biomarkers Prev.*, **16**, 165–168.
  29. Freathy, R.M., Timpson, N.J., Lawlor, D.A., Pouta, A., Ben-Shlomo, Y., Ruokonen, A., Ebrahim, S., Shields, B., Zeggini, E., Weedon, M.N. *et al.* (2008) Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. *Diabetes*, **57**, 1419–1426.
  30. Chinn, S. (2000) A simple method for converting an odds ratio to effect size for use in meta-analysis. *Stat. Med.*, **19**, 3127–3131.
  31. Prokopenko, I., Langenberg, C., Florez, J., Saxena, R., Soranzo, N., Thorleifsson, G., Loos, R., Manning, A., Jackson, A., Aulchenko, Y. *et al.* (2009) Variants in MTNR1B influence fasting glucose levels. *Nat. Genet.*, **41**, 77–81.
  32. Grarup, N., Rose, C.S., Andersson, E.A., Andersen, G., Nielsen, A.L., Albrechtsen, A., Clausen, J.O., Rasmussen, S.S., Jørgensen, T., Sandbæk, A. *et al.* (2007) Studies of association of variants near the HHEX, CDKN2A/B and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects—validation and extension of genome-wide association studies. *Diabetes*, **56**, 3105–3111.
  33. Pascoe, L., Tura, A., Patel, S.K., Ibrahim, I.M., Ferrannini, E., Consortium, T.R., Consortium, T.U.T.D.G., Zeggini, E., Weedon, M.N., Mari, A. *et al.* (2007) Common variants of the novel type 2 diabetes genes, CDKAL1 and HHEX/IDE, are associated with decreased pancreatic  $\beta$ -cell function. *Diabetes*, **56**, 3101–3104.
  34. Abate, N., Haffner, S.M., Garg, A., Peshock, R.M. and Grundy, S.M. (2002) Sex steroid hormones, upper body obesity, and insulin resistance. *J. Clin. Endocrinol. Metabol.*, **87**, 4522–4527.
  35. Svartberg, J., Jenssen, T., Sundsfjord, J. and Jorde, R. (2004) The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. *Diabetol. Metabol.*, **30**, 29–34.
  36. Kalme, T., Seppala, M., Qiao, Q., Koistinen, R., Nissinen, A., Harrela, M., Loukovaara, M., Leinonen, P. and Tuomilehto, J. (2005) Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. *J. Clin. Endocrinol. Metabol.*, **90**, 1550–1556.
  37. Jayagopal, V., Kilpatrick, E.S., Jennings, P.E., Holding, S., Hepburn, D.A. and Atkin, S.L. (2004) The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. *Diabetes care*, **27**, 278–280.
  38. Stoney, R.M., Walker, K.Z., Best, J.D., Ireland, P.D., Giles, G.G. and O’Dea, K. (1998) Do postmenopausal women with NIDDM have a reduced capacity to deposit and conserve lower-body fat? *Diabetes care*, **21**, 828–830.